Current use of cardiac biomarkers in various heart conditions.

Current use of cardiac biomarkers in various heart conditions. Endocr Metab Immune Disord Drug Targets. 2020 Aug 31;: Authors: Khan S, Rasool ST Abstract Biomarkers are increasingly recognized to have significant clinical value in early identification and progression of various cardiovascular diseases. There are many heart conditions such as Congestive heart failure (CHF), ischemic heart diseases (IHD), and diabetic cardiomyopathy (DCM) and cardiac remodeling in which the severity of the cardiac pathology can be mirrored through these biomarker or cardiac biomarkers. From the emergency department (ED) evaluation of acute coronary syndromes (ACS) or suspected acute myocardial infarction (AMI) with cardiac marker Troponin to the diagnosis of chronic conditions like Heart Failure (HF) with natriuretic peptides, like B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (Nt-proBNP) and mid regional pro-atrial natriuretic peptide (MR-proANP), their use is con-tinuously increasing. Their clinical importance has led to the discovery of newer biomarkers such as the soluble source of tumorigenicity 2 (sST2), galectin-3 (Gal-3), growth differentiation factor-15 (GDF-15) and various micro ribonucleic acids (miRNAs). Since cardiac pathophysiology involves a complex interplay between inflammatory, genetic, neurohormonal, and biochemical levels, these biomarkers could be enzymes, hormones, and biologic substances showing card...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Endocrinology Authors: Tags: Endocr Metab Immune Disord Drug Targets Source Type: research